Mandate

PPM Ventures and Triton – acquisition of Pharmacia Diagnostics

May 12, 2005

Triton, the European private equity firm, and PPM Ventures Ltd, the private equity business within Prudential Corporation plc, the UK financial services group, has agreed to acquire Pharmacia Diagnostics AB, the Swedish based in-vitro allergy and autoimmune diagnostic testing business of Pfizer Inc, the US-based health care company, for USD 575m.

Vinge acted for Triton and PPM Ventures Ltd.

Johan Cederlund, Christina Kokko (responsible partners)
Sara Mindus (associate)

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026